#1ResMed Acquisition of MEDIFOX DAN June 14, 2022#2Forward-looking statements Historical financial and operating data in this presentation reflect the consolidated results of ResMed Inc., its subsidiaries, and its legal entities, for the periods indicated. This presentation includes financial information prepared in accordance with accounting principles generally accepted in the United States, or GAAP, as well as other financial measures referred to as non-GAAP. The non-GAAP financial measures in this presentation, which include non-GAAP Income from Operations, non-GAAP Net Income, and non-GAAP Diluted Earnings per Share, should be considered in addition to, but not as substitutes for, the information prepared in accordance with GAAP. For reconciliations of the non-GAAP financial measures to the most comparable GAAP measures, please refer to the earnings release associated with the relevant reporting period, which can be found on the investor relations section of our corporate website (investor.resmed.com). In addition to historical information, this presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on ResMed's current expectations of future revenue or earnings, new product development, new product launches, new markets for its products, integration of acquisitions, leveraging of strategic investments, litigation, tax outlook, and the length and severity of the recent coronavirus outbreak, including its impacts across our business and operations. Forward-looking statements can generally be identified by terminology such as "may", "will", "should", "expects", "intends", "plans", "anticipates”, “believes", "estimates”, “predicts”, “potential", or "continue", or variations of these terms, or the negative of these terms or other comparable terminology. ResMed's expectations, beliefs, and forecasts are expressed in good faith and are believed to have a reasonable basis, but actual results could differ materially from those stated or implied by these forward-looking statements. ResMed assumes no obligation to update the forward-looking information in this presentation, whether as a result of new information, future events, or otherwise. For further discussion of the various factors that could impact actual events or results, please review the "Risk Factors" identified in ResMed's quarterly and annual reports filed with the SEC. All forward-looking statements included in this presentation should be considered in the context of these risks. Investors and prospective investors are cautioned not to unduly rely on our forward-looking statements. 22022 ResMed. Company confidential.#3Creation of a global leader in out-of-hospital software ResMed Leading provider of mission critical software in out-of- hospital markets across the U.S. brightree by ResMed MatrixCare by ResMed 32022 ResMed. Company confidential. + MEDIFOX DAN Leading provider of end-to-end software solutions for home health providers, nursing homes, and outpatient therapy practices in Germany#4Creation of a global leader in out-of-hospital software (cont'd) 1 Strategic expansion of software portfolio into Europe Strategically aligned addition to SaaS portfolio, further supporting ResMed's position as a leader in digital health 2 Acquisition of market leader in Germany 3 Combination positioned to accelerate innovation and scale Attractive financial 4 profile Accelerates ResMed's efforts to bring software technology along with digital innovation to out-of-hospital care settings Opportunity to accelerate MEDIFOX DAN's innovation together with ResMed's deep experience in cloud and data to build complementary offering at scale Immediately accretive to non-GAAP EPS, with a high proportion of recurring software revenues 42022 ResMed. Company confidential.#5MEDIFOX DAN snapshot ^ ^ ^ ^ At a glance Leading software provider within growing German healthcare sector supported by structural growth drivers End-to-end solution and the operating system of choice used daily by 300K+ caregivers Mission-critical technology deeply embedded in workflows within a large, growing and highly loyal customer base High-caliber and experienced management team with a proven track record of delivering profitable growth $83M PF Revenue (1,2) (CY 2021) By the numbers $35M PF Adj. EBITDA(1,2) (CY 2021) 14% Organic Revenue CAGR(2) (CY19 - CY21) 8K+ Customers 300K+ 600 Caregivers that use platform daily Employees 1. Based on a EUR/USD rate of 1.053. 2. Pro forma adjusted for acquisitions. 52022 ResMed. Company confidential.#6Comprehensive software solution across care provider workflows Customers Software: Core modules & extensions Segments accounting for majority of revenue today Home Health Nursing Home Outpatient Therapy Billing & administration Care planning & documentation (Al-based) Staff rostering & task management (Al-based) Route planning Stakeholder portal 62022 ResMed. Company confidential. E-Learning Other extension modules (e.g. Mobile care, MyDay, Time)#7Care providers in Germany are increasingly turning to technology for efficiencies MEDIFOX DAN complements ResMed's existing presence in Germany Aging and more acute population, with rising chronic condition prevalence German Healthcare Industry Tailwinds Skilled labor shortage resulting in rising care ratios (patients per caregiver) Government digitization regulations supporting Increased need for software to aid care planning Increased need for efficiency gains via software Software enables faster provider reimbursement and reporting Together with MEDIFOX DAN, ResMed is positioned to support and enhance care in Germany Source: Industry research, ResMed analysis. 72022 ResMed. Company confidential.#8MEDIFOX DAN accelerates the out-of-hospital software strategy and solution suite brightree by Out-of-Hospital Care Ecosystem Software Solutions and Data III ResMed MEDIFOX DAN 000 00 0 0 0 Mission critical software and data solutions ● Billing and administration ● Clinical care plan Documentation ● Personnel planning MatrixCare by ResMed Home Medical Equipment Providers Pharmacy/ Infusion Outpatient Home Skilled Therapy Health Nursing Senior Living Hospice/ Palliative Care Private Duty Life Plan Communities 82022 ResMed. Company confidential. Comprehensive software platform for out-of-hospital care#9Transaction summary . Enterprise value of approximately $1.0B(1) (€950M) Transaction details ● All-cash consideration, to be financed with existing cash and debt capacity Financial highlights Timing • CY 2021 PF Revenue of $83M(1,2) and PF Adj. EBITDA of $35M(1,2) Strong double-digit organic growth profile - CY 2019-21 organic revenue CAGR: 14% (3) Immediately accretive to non-GAAP EPS (4) Closing expected in 2H of CY 2022 Subject to regulatory clearances 1. Based on a EUR/USD rate of 1.053. 2. PF Revenue includes adjustments for acquisitions, and PF Adj. EBITDA includes adjustments for acquisitions, income from JVs, and other customary add-backs for non-recurring items. 3. Based on pro forma revenue adjusted for acquisitions. 4. Post deal close 92022 ResMed. Company confidential.#10Q&A ResMed